Trade Reata Pharma - RETA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 172.17 |
| Open | 172.23 |
| 1-Year Change | 680.38% |
| Day's Range | 172.19 - 172.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 25, 2023 | 172.23 | 0.02 | 0.01% | 172.21 | 172.32 | 172.18 |
| Sep 22, 2023 | 172.17 | 0.00 | 0.00% | 172.17 | 172.19 | 172.11 |
| Sep 21, 2023 | 172.02 | -0.08 | -0.05% | 172.10 | 172.21 | 171.98 |
| Sep 20, 2023 | 172.07 | 0.10 | 0.06% | 171.97 | 172.07 | 171.97 |
| Sep 19, 2023 | 171.97 | 0.14 | 0.08% | 171.83 | 172.00 | 171.83 |
| Sep 18, 2023 | 171.90 | 0.08 | 0.05% | 171.82 | 171.93 | 171.60 |
| Sep 15, 2023 | 171.83 | -0.08 | -0.05% | 171.91 | 172.00 | 171.69 |
| Sep 14, 2023 | 171.92 | 0.05 | 0.03% | 171.87 | 171.93 | 171.84 |
| Sep 13, 2023 | 171.87 | 0.00 | 0.00% | 171.87 | 171.94 | 171.81 |
| Sep 12, 2023 | 171.83 | 1.44 | 0.85% | 170.39 | 171.91 | 170.08 |
| Sep 11, 2023 | 170.82 | 0.95 | 0.56% | 169.87 | 170.97 | 169.87 |
| Sep 8, 2023 | 170.15 | 0.58 | 0.34% | 169.57 | 170.23 | 169.57 |
| Sep 7, 2023 | 170.02 | 0.60 | 0.35% | 169.42 | 170.11 | 169.42 |
| Sep 6, 2023 | 169.51 | 0.34 | 0.20% | 169.17 | 169.60 | 169.05 |
| Sep 5, 2023 | 169.61 | 0.94 | 0.56% | 168.67 | 169.83 | 168.67 |
| Sep 1, 2023 | 169.13 | 0.31 | 0.18% | 168.82 | 169.36 | 168.82 |
| Aug 31, 2023 | 168.83 | 0.22 | 0.13% | 168.61 | 169.11 | 168.61 |
| Aug 30, 2023 | 168.53 | -0.22 | -0.13% | 168.75 | 169.03 | 168.53 |
| Aug 29, 2023 | 168.75 | -0.07 | -0.04% | 168.82 | 168.94 | 168.66 |
| Aug 28, 2023 | 168.77 | -0.10 | -0.06% | 168.87 | 169.17 | 168.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Reata Pharma Company profile
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Reata Pharmaceuticals Inc revenues increased 27% to $11.5M. Net loss before extraordinary items increased 10% to $297.4M. Revenues reflect License and milestone increase of 71% to $8M. Higher net loss reflects Other Non Operating I/E increase from $21.9M to $46.7M (expense), General and administrative - Balancing increase of 44% to $65.8M (expense).
| Industry: | Biopharmaceuticals |
5320 Legacy Dr
PLANO
TEXAS 75024-3127
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com